The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

Greater proportion of upadacitinib-treated patients attained near-complete skin clearance in the head and neck region.

The company has previously reported positive data for its PDE4 inhibitor, orismilast, in psoriasis, hidradenitis suppurativa, ...

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

When childhood atopic dermatitis persists into adulthood, the large reduction in quality of life suggests that the price of ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

New proteomic analyses show that rezpegaldesleukin increases the protein levels of immune-regulating pathways while reducing ...

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...